Table 2.
Risk factors | Proximal colon cancer |
Distal colon cancer |
Rectum cancer |
P for overall heterogeneityb | P for linear heterogeneityc | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cecum | Ascending colon | Transverse colon | Overall | Descending colon | Sigmoid colon | Overall | Rectosigmoid | Rectum | Overall | |||
n=474 | n=633 | n=250 | n=1357 | n=221 | n=750 | n=971 | n=202 | n=528 | n=730 | |||
Age, per 5 years | ||||||||||||
HR | 1.43 | 1.62 | 1.45 | 1.51 | 1.42 | 1.39 | 1.39 | 1.32 | 1.37 | 1.36 | ||
95% CI | 1.35–1.52 | 1.53–1.71 | 1.34–1.57 | 1.45–1.56 | 1.3–1.55 | 1.32–1.45 | 1.34–1.45 | 1.2–1.44 | 1.29–1.45 | 1.29–1.42 | <0.001 | 0.04 |
Ptrend | 1.43 | 1.62 | 1.45 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
P for heterogeneity within major subsitesb | 0.006 | 0.72 | 0.52 | |||||||||
Female sex | ||||||||||||
HR | 0.63 | 1.73 | 0.61 | 0.93 | 0.83 | 0.54 | 0.65 | 0.84 | 0.68 | 0.70 | ||
95% CI | 0.51–0.78 | 1.40–2.15 | 0.51–0.72 | 0.81–1.05 | 0.6–1.16 | 0.41–0.72 | 0.56–0.76 | 0.61–1.17 | 0.56–0.84 | 0.59–0.84 | <0.001 | 0.70 |
P | <.0001 | <.0001 | <.0001 | 0.24 | 0.27 | <.0001 | <.0001 | 0.31 | 0.0003 | <.0001 | ||
P for heterogeneity within main subsitesb | <0.001 | 0.10 | 0.29 | |||||||||
Family history of colorectal cancer | ||||||||||||
HR | 1.55 | 1.66 | 1.86 | 1.65 | 1.22 | 1.46 | 1.41 | 1.26 | 1.10 | 1.14 | ||
95%CI | 1.25–1.91 | 1.39–1.98 | 1.41–2.46 | 1.46–1.87 | 0.88–1.70 | 1.23–1.73 | 1.21–1.64 | 0.89–1.79 | 0.88–1.37 | 0.94–1.37 | 0.02 | 0.004 |
P | <0.001 | <0.001 | <0.001 | <0.001 | 0.24 | <.0001 | <0.001 | 0.19 | 0.42 | 0.17 | ||
P for heterogeneity within main subsitesb | 0.57 | 0.37 | 0.52 | |||||||||
Endoscopic screening | ||||||||||||
HR | 0.75 | 0.71 | 0.67 | 0.72 | 0.45 | 0.36 | 0.38 | 0.53 | 0.50 | 0.51 | ||
95% CI | 0.54–1.03 | 0.53–0.94 | 0.41–1.08 | 0.59–0.87 | 0.24–0.83 | 0.25–0.51 | 0.28–0.51 | 0.30–0.94 | 0.34–0.72 | 0.37–0.69 | 0.02 | 0.005 |
P | 0.07 | 0.02 | 0.10 | <0.001 | 0.01 | <0.001 | <0.001 | 0.03 | <0.001 | <0.001 | ||
P for heterogeneity within main subsitesb | 0.94 | 0.62 | 0.83 | |||||||||
Regular aspirin use | ||||||||||||
HR | 0.76 | 0.69 | 0.67 | 0.71 | 0.62 | 0.73 | 0.70 | 0.65 | 0.81 | 0.76 | ||
95% CI | 0.63–0.92 | 0.58–0.81 | 0.51–0.87 | 0.63–0.79 | 0.46–0.83 | 0.62–0.85 | 0.61–0.80 | 0.47–0.88 | 0.68–0.98 | 0.65–0.89 | 0.65 | 0.51 |
P | 0.005 | <0.001 | 0.003 | <0.001 | <0.001 | <0.001 | <0.001 | 0.005 | 0.03 | <0.001 | ||
P for heterogeneity within main subsitesb | 0.76 | 0.39 | 0.14 |
Age- and cohort-stratified Cox proportional hazards model was used with further adjustment for race, height (continuous), family history of colorectal cancer (yes or no), history of lower gastrointestinal endoscopic screening (yes or no), body mass index (continuous), pack-years of smoking (continuous), physical activity (continuous), alcohol intake (continuous), and regular aspirin use (yes or no). When age and sex are the main exposures, the model was only adjusted for each other of the two variables.
Overall heterogeneity was tested by using the meta-regression method with a subsite-specific random effect term as a nominal variable.
Linear heterogeneity was tested by using the meta-regression method with a subsite-specific random effect term as an ordinal variable.